Cargando…

Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern

OBJECTIVE: To investigate the prevalence and determinants of virologic failure and acquired drug resistance-associated mutations (DRMs) in HIV-infected children and adolescents in rural Tanzania. DESIGN: Prospective cohort study with cross-sectional analysis. METHODS: All children 18 years or less a...

Descripción completa

Detalles Bibliográficos
Autores principales: Muri, Lukas, Gamell, Anna, Ntamatungiro, Alex J., Glass, Tracy R., Luwanda, Lameck B., Battegay, Manuel, Furrer, Hansjakob, Hatz, Christoph, Tanner, Marcel, Felger, Ingrid, Klimkait, Thomas, Letang, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131685/
https://www.ncbi.nlm.nih.gov/pubmed/27677163
http://dx.doi.org/10.1097/QAD.0000000000001273
_version_ 1782470941906829312
author Muri, Lukas
Gamell, Anna
Ntamatungiro, Alex J.
Glass, Tracy R.
Luwanda, Lameck B.
Battegay, Manuel
Furrer, Hansjakob
Hatz, Christoph
Tanner, Marcel
Felger, Ingrid
Klimkait, Thomas
Letang, Emilio
author_facet Muri, Lukas
Gamell, Anna
Ntamatungiro, Alex J.
Glass, Tracy R.
Luwanda, Lameck B.
Battegay, Manuel
Furrer, Hansjakob
Hatz, Christoph
Tanner, Marcel
Felger, Ingrid
Klimkait, Thomas
Letang, Emilio
author_sort Muri, Lukas
collection PubMed
description OBJECTIVE: To investigate the prevalence and determinants of virologic failure and acquired drug resistance-associated mutations (DRMs) in HIV-infected children and adolescents in rural Tanzania. DESIGN: Prospective cohort study with cross-sectional analysis. METHODS: All children 18 years or less attending the paediatric HIV Clinic of Ifakara and on antiretroviral therapy (ART) for at least 12 months were enrolled. Participants with virologic failure were tested for HIV-DRM. Pre-ART samples were used to discriminate acquired and transmitted resistances. Multivariate logistic regression analysis identified factors associated with virologic failure and the acquisition of HIV-DRM. RESULTS: Among 213 children on ART for a median of 4.3 years, 25.4% failed virologically. ART-associated DRM were identified in 90%, with multiclass resistances in 79%. Pre-ART data suggested that more than 85% had acquired key mutations during treatment. Suboptimal adherence [odds ratio (OR) = 3.90; 95% confidence interval (CI) 1.11–13.68], female sex (aOR = 2.57; 95% CI 1.03–6.45), and current nonnucleoside reverse transcriptase inhibitor-based ART (aOR = 7.32; 95% CI 1.51–35.46 compared with protease inhibitor-based) independently increased the odds of virologic failure. CD4(+) T-cell percentage (aOR = 0.20; 0.10–0.40 per additional 10%) and older age at ART initiation (aOR = 0.84 per additional year of age; 95% CI 0.73–0.97) were protective (also in predicting acquired HIV-DRM). At the time of virologic failure, less than 5% of the children fulfilled the WHO criteria for immunologic failure. CONCLUSION: Virologic failure rates in children and adolescents were high, with the majority of ART-failing children harbouring HIV-DRM. The WHO criteria for immunologic treatment failure yielded an unacceptably low sensitivity. Viral load monitoring is urgently needed to maintain future treatment options for the millions of African children living with HIV.
format Online
Article
Text
id pubmed-5131685
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-51316852016-12-15 Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern Muri, Lukas Gamell, Anna Ntamatungiro, Alex J. Glass, Tracy R. Luwanda, Lameck B. Battegay, Manuel Furrer, Hansjakob Hatz, Christoph Tanner, Marcel Felger, Ingrid Klimkait, Thomas Letang, Emilio AIDS Clinical Science OBJECTIVE: To investigate the prevalence and determinants of virologic failure and acquired drug resistance-associated mutations (DRMs) in HIV-infected children and adolescents in rural Tanzania. DESIGN: Prospective cohort study with cross-sectional analysis. METHODS: All children 18 years or less attending the paediatric HIV Clinic of Ifakara and on antiretroviral therapy (ART) for at least 12 months were enrolled. Participants with virologic failure were tested for HIV-DRM. Pre-ART samples were used to discriminate acquired and transmitted resistances. Multivariate logistic regression analysis identified factors associated with virologic failure and the acquisition of HIV-DRM. RESULTS: Among 213 children on ART for a median of 4.3 years, 25.4% failed virologically. ART-associated DRM were identified in 90%, with multiclass resistances in 79%. Pre-ART data suggested that more than 85% had acquired key mutations during treatment. Suboptimal adherence [odds ratio (OR) = 3.90; 95% confidence interval (CI) 1.11–13.68], female sex (aOR = 2.57; 95% CI 1.03–6.45), and current nonnucleoside reverse transcriptase inhibitor-based ART (aOR = 7.32; 95% CI 1.51–35.46 compared with protease inhibitor-based) independently increased the odds of virologic failure. CD4(+) T-cell percentage (aOR = 0.20; 0.10–0.40 per additional 10%) and older age at ART initiation (aOR = 0.84 per additional year of age; 95% CI 0.73–0.97) were protective (also in predicting acquired HIV-DRM). At the time of virologic failure, less than 5% of the children fulfilled the WHO criteria for immunologic failure. CONCLUSION: Virologic failure rates in children and adolescents were high, with the majority of ART-failing children harbouring HIV-DRM. The WHO criteria for immunologic treatment failure yielded an unacceptably low sensitivity. Viral load monitoring is urgently needed to maintain future treatment options for the millions of African children living with HIV. Lippincott Williams & Wilkins 2017-01-02 2016-12-02 /pmc/articles/PMC5131685/ /pubmed/27677163 http://dx.doi.org/10.1097/QAD.0000000000001273 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Clinical Science
Muri, Lukas
Gamell, Anna
Ntamatungiro, Alex J.
Glass, Tracy R.
Luwanda, Lameck B.
Battegay, Manuel
Furrer, Hansjakob
Hatz, Christoph
Tanner, Marcel
Felger, Ingrid
Klimkait, Thomas
Letang, Emilio
Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern
title Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern
title_full Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern
title_fullStr Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern
title_full_unstemmed Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern
title_short Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern
title_sort development of hiv drug resistance and therapeutic failure in children and adolescents in rural tanzania: an emerging public health concern
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131685/
https://www.ncbi.nlm.nih.gov/pubmed/27677163
http://dx.doi.org/10.1097/QAD.0000000000001273
work_keys_str_mv AT murilukas developmentofhivdrugresistanceandtherapeuticfailureinchildrenandadolescentsinruraltanzaniaanemergingpublichealthconcern
AT gamellanna developmentofhivdrugresistanceandtherapeuticfailureinchildrenandadolescentsinruraltanzaniaanemergingpublichealthconcern
AT ntamatungiroalexj developmentofhivdrugresistanceandtherapeuticfailureinchildrenandadolescentsinruraltanzaniaanemergingpublichealthconcern
AT glasstracyr developmentofhivdrugresistanceandtherapeuticfailureinchildrenandadolescentsinruraltanzaniaanemergingpublichealthconcern
AT luwandalameckb developmentofhivdrugresistanceandtherapeuticfailureinchildrenandadolescentsinruraltanzaniaanemergingpublichealthconcern
AT battegaymanuel developmentofhivdrugresistanceandtherapeuticfailureinchildrenandadolescentsinruraltanzaniaanemergingpublichealthconcern
AT furrerhansjakob developmentofhivdrugresistanceandtherapeuticfailureinchildrenandadolescentsinruraltanzaniaanemergingpublichealthconcern
AT hatzchristoph developmentofhivdrugresistanceandtherapeuticfailureinchildrenandadolescentsinruraltanzaniaanemergingpublichealthconcern
AT tannermarcel developmentofhivdrugresistanceandtherapeuticfailureinchildrenandadolescentsinruraltanzaniaanemergingpublichealthconcern
AT felgeringrid developmentofhivdrugresistanceandtherapeuticfailureinchildrenandadolescentsinruraltanzaniaanemergingpublichealthconcern
AT klimkaitthomas developmentofhivdrugresistanceandtherapeuticfailureinchildrenandadolescentsinruraltanzaniaanemergingpublichealthconcern
AT letangemilio developmentofhivdrugresistanceandtherapeuticfailureinchildrenandadolescentsinruraltanzaniaanemergingpublichealthconcern